SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIBs recent price uptick and attempts to break through resistance are driving speculation about a renewed meme-coin rally, with traders watching for a breakout. The community is split between accumulation and bullish hopes for a pump and frustration over prolonged sideways trading, weak utility, and limited token burns.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is drawing attention as shares break to fresh highs, alongside positive drug developments including FDA approval of Juvmo for Parkinsons disease and encouraging Phase 3 lymphoma results with Genmab. Traders are broadly bullish on the momentum, though some question whether the breakout can hold.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FET is drawing attention amid a rebound and renewed rotation into AI-related crypto tokens, with traders focusing on Fetch.ais autonomous-agent and ASI ecosystem. Bulls point to improving momentum and accumulation, while skeptics cite resistance levels, past underperformance, and dependence on broader crypto conditions.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives live Supply Squeeze governance proposal is drawing attention, with traders focused on the possibility that approval would double INJs deflation rate; bullish posts also point to staking, burns and the chains RWA and finance activity. Sentiment is sharply divided between accumulation and long-term optimism and skepticism about INJs prolonged weakness, while some users complain that repeated Nonja promotion is cluttering discussion.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is drawing attention for its strong rally and repeated 52-week highs, with bullish traders pointing to momentum and demand for its data-security platform. Others argue the stock looks expensive and cite insider selling, managements guidance, and lagging performance versus cybersecurity peers as reasons for caution.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention on bullish breakout setups, with traders citing chart patterns and its capped token supply. Optimism about Compounds institutional-market push and V4 roadmap is tempered by complaints that the token has lagged other crypto assets.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is drawing attention after a sharp selloff, with traders debating whether shares not accepted in the substantial issuer bid are adding selling pressure; that explanation remains speculation. Bearish posts also cite elevated fuel costs and earnings risk, while bulls point to potential buybacks and argue that short-selling is worsening the decline.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Ethereums sharp rebound and breakout have driven attention, with traders citing institutional adoption, ETF flows, and crypto-regulation optimism as supportive themes. Bullish momentum is contested by concerns about thin volume, pullbacks, and whether gains can hold.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow shares are under pressure amid investor frustration over repeated revenue-guidance misses and VEVYEs weak monetization, including pricing and gross-to-net concerns. Long-term bulls view the pullback and insider buying as an opportunity, while skeptics want cleaner execution before trusting the growth outlook.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is drawing attention after a sharp pullback amid an FTC/USDA inquiry into agricultural-equipment practices and a broker downgrade. Traders debate whether the selloff is an overreaction because the inquiry is industry-wide and CATs business is weighted toward construction, mining and power; dip buyers are looking for a rebound while bearish voices point to continued weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Who is Claire Mazumdar? Meet Kiran Mazumdar-Shaw’s chosen successor at Biocon

Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw has chosen her niece Claire Mazumdar to succeed her as the biotech entrepreneur laid out a succession plan for India’s leading biotech firm. Mazumdar-Shaw (73), who has no children, in a post on X, confirmed reports about the succession planning in Biocon and that she has choosen niece […]

Mazumdar-Shaw picks niece Claire as Biocon successor

India Business News: Kiran Mazumdar-Shaw, founder and chairperson of Biocon, has found her successor within the family. She outlined a gradual succession plan, naming her .

The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garage

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who built the company from a garage into a global biotech leader, Kiran is ensuring continuity by handing over to a science-driven leader while remaining at the helm during the transition.

Biocon Founder Kiran Mazumdar-Shaw Proposes Niece As Successor Of India’s Biopharma Major

Biocon founder and chairperson Kiran Mazumdar-Shaw has proposed her niece as her successor. In a formal succession plan for the company, the 73-year-old matriarch has put forward the name of Claire Mazumdar, currently the chief executive officer of Bicara Therapeutics

Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed

Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.

Sensex, Nifty Poised For A Cautious Opening; Reliance, Infosys, Fortis, Wipro, Biocon, Vikram Solar, LTIMindtree Stocks Are In Focus

Equity

Indian conglomerate Reliance Industries is expected to post its Q2 earnings today.

Will Trump’s 100% Tariffs Derail Indian Pharma Stocks? SEBI Analyst Flags Key Levels For Traders

The new U.S. duty has already triggered a slide in major Asian pharma names, raising concerns about how Indian peers will react in the coming weeks.

India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

Top Breakout Stock Ideas: Analysts Pick Biocon, KFin Tech, Poly Medicure, Sammaan Capital And More

Stocks such as Elgi Equipment, Supriya Life and Bajaj Consumer are on the breakout radar with upside potential, say analysts. 


Trading Radar For September 18: Biocon, Indosolar, Yes Bank, Cochin Shipyard, Dixon, Hyundai Stocks Are On Investors’ Watchlist

The broader markets are expected to open on a positive note after the US Federal Reserve slashed the benchmark interest rate by 25 basis points.

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	0.97	--	--	N/A
Q1 '26	1.00	0.87	-13.43%	MISSED
Q4 '25	1.17	--	--	N/A
Q3 '25	1.17	0.95	-18.76%	MISSED
Q2 '25	0.75	0.76	1.36%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIOCON.NSE Earnings

Upcoming Earnings: Q2 '26

Historical Earnings